ImmunityBio, Inc. Stock Prediction and Forecast [IBRX]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 24 Feb 2026, 03:56 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:24 UTC
![Video preview for ImmunityBio, Inc. Stock Prediction and Forecast [IBRX]](https://i.ytimg.com/vi/dbN2sGZjswQ/hqdefault.jpg)
AI-generated source summary
ImmunityBio (IBRX) shows a bullish short-term and long-term outlook based on moving averages and MACD signals. Despite a recent sell-off in the broader market, the stock has exhibited strong upward momentum and positive investor sentiment. The company's financial performance, while having some negative aspects like a negative P/E ratio, is bolstered by significant new agreements and approvals. Technically, the stock is trading above key moving averages and has shown a strong rally since its pivot low on February 13, 2026. Future resistance is anticipated around $12.94, with support expected at $8.70. Given these factors, IBRX is considered a buy candidate.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.